UMOD and chronic kidney disease: Using two-sample Mendelian randomization across four GWAS consortia demonstrated that higher urinary uromodulin levels were significantly associated with lower eGFR, heightened odds for eGFR decline or CKD, and elevated systolic and diastolic blood pressure.